Butyrate production in patients with end-stage renal disease

Matty L. Terpstra, Marjan J. Sinnige, Floor Hugenholtz, Hessel Peters-Sengers, Ester B. M. Remmerswaal, Suzanne E. Geerlings, Frederike J. Bemelman

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Chronic kidney disease (CKD) is associated with a decreased intestinal barrier function, causing bacterial translocation over the intestinal wall and triggering a systemic inflammatory response. Butyrate, a short-chain fatty acid produced by certain bacterial strains, is considered instrumental to keep the intestinal barrier intact. There are indications that a decreased amount of these specific bacterial species is part of the cause of the decreased intestinal barrier function in CKD. The aim of this study is (i) to determine if Dutch patients with end-stage renal disease (ESRD) have a decreased amount of butyrateproducing species and butyrate-producing capacity and (ii) whether this correlates with systemic inflammation. Methods: We used qPCR to evaluate the most abundant butyrate-producing species F. prauznitzii, E. rectale and Roseburia spp. and the BCoAT gene, which reflects the butyrogenic capacity of the intestinal microbiota. Fecal samples were collected from healthy kidney donors (n=15), preemptive renal transplant recipients (n=4) and dialysis patients (n=31). Markers of inflammation (CRP and IL-6) and intestinal permeability (D-lactate) were measured in plasma. Results: Patients with ESRD did not have a significantly decreased amount F. prauznitzii, E. rectale and Roseburia spp. or the BCoAT gene. Neither was there a significant correlation with CRP, IL-6 or D-lactate. On the individual level, there were some patients with decreased BCoAT levels and increased levels of CRP, IL-6 and D-lactate. Conclusions: Patients with ESRD do not have a decreased amount of the most abundant butyrate-producing species nor a decreased butyrate-producing capacity.
Original languageEnglish
Pages (from-to)87-101
JournalInternational Journal of Nephrology and Renovascular Disease
Volume12
DOIs
Publication statusPublished - 2019

Cite this

Terpstra, M. L., Sinnige, M. J., Hugenholtz, F., Peters-Sengers, H., Remmerswaal, E. B. M., Geerlings, S. E., & Bemelman, F. J. (2019). Butyrate production in patients with end-stage renal disease. International Journal of Nephrology and Renovascular Disease, 12, 87-101. https://doi.org/10.2147/IJNRD.S200297
Terpstra, Matty L. ; Sinnige, Marjan J. ; Hugenholtz, Floor ; Peters-Sengers, Hessel ; Remmerswaal, Ester B. M. ; Geerlings, Suzanne E. ; Bemelman, Frederike J. / Butyrate production in patients with end-stage renal disease. In: International Journal of Nephrology and Renovascular Disease. 2019 ; Vol. 12. pp. 87-101.
@article{7ddcd78047114f199e0cc8bfadd18c8a,
title = "Butyrate production in patients with end-stage renal disease",
abstract = "Background: Chronic kidney disease (CKD) is associated with a decreased intestinal barrier function, causing bacterial translocation over the intestinal wall and triggering a systemic inflammatory response. Butyrate, a short-chain fatty acid produced by certain bacterial strains, is considered instrumental to keep the intestinal barrier intact. There are indications that a decreased amount of these specific bacterial species is part of the cause of the decreased intestinal barrier function in CKD. The aim of this study is (i) to determine if Dutch patients with end-stage renal disease (ESRD) have a decreased amount of butyrateproducing species and butyrate-producing capacity and (ii) whether this correlates with systemic inflammation. Methods: We used qPCR to evaluate the most abundant butyrate-producing species F. prauznitzii, E. rectale and Roseburia spp. and the BCoAT gene, which reflects the butyrogenic capacity of the intestinal microbiota. Fecal samples were collected from healthy kidney donors (n=15), preemptive renal transplant recipients (n=4) and dialysis patients (n=31). Markers of inflammation (CRP and IL-6) and intestinal permeability (D-lactate) were measured in plasma. Results: Patients with ESRD did not have a significantly decreased amount F. prauznitzii, E. rectale and Roseburia spp. or the BCoAT gene. Neither was there a significant correlation with CRP, IL-6 or D-lactate. On the individual level, there were some patients with decreased BCoAT levels and increased levels of CRP, IL-6 and D-lactate. Conclusions: Patients with ESRD do not have a decreased amount of the most abundant butyrate-producing species nor a decreased butyrate-producing capacity.",
author = "Terpstra, {Matty L.} and Sinnige, {Marjan J.} and Floor Hugenholtz and Hessel Peters-Sengers and Remmerswaal, {Ester B. M.} and Geerlings, {Suzanne E.} and Bemelman, {Frederike J.}",
year = "2019",
doi = "10.2147/IJNRD.S200297",
language = "English",
volume = "12",
pages = "87--101",
journal = "International Journal of Nephrology and Renovascular Disease",
issn = "1178-7058",

}

Terpstra, ML, Sinnige, MJ, Hugenholtz, F, Peters-Sengers, H, Remmerswaal, EBM, Geerlings, SE & Bemelman, FJ 2019, 'Butyrate production in patients with end-stage renal disease' International Journal of Nephrology and Renovascular Disease, vol. 12, pp. 87-101. https://doi.org/10.2147/IJNRD.S200297

Butyrate production in patients with end-stage renal disease. / Terpstra, Matty L.; Sinnige, Marjan J.; Hugenholtz, Floor; Peters-Sengers, Hessel; Remmerswaal, Ester B. M.; Geerlings, Suzanne E.; Bemelman, Frederike J.

In: International Journal of Nephrology and Renovascular Disease, Vol. 12, 2019, p. 87-101.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Butyrate production in patients with end-stage renal disease

AU - Terpstra, Matty L.

AU - Sinnige, Marjan J.

AU - Hugenholtz, Floor

AU - Peters-Sengers, Hessel

AU - Remmerswaal, Ester B. M.

AU - Geerlings, Suzanne E.

AU - Bemelman, Frederike J.

PY - 2019

Y1 - 2019

N2 - Background: Chronic kidney disease (CKD) is associated with a decreased intestinal barrier function, causing bacterial translocation over the intestinal wall and triggering a systemic inflammatory response. Butyrate, a short-chain fatty acid produced by certain bacterial strains, is considered instrumental to keep the intestinal barrier intact. There are indications that a decreased amount of these specific bacterial species is part of the cause of the decreased intestinal barrier function in CKD. The aim of this study is (i) to determine if Dutch patients with end-stage renal disease (ESRD) have a decreased amount of butyrateproducing species and butyrate-producing capacity and (ii) whether this correlates with systemic inflammation. Methods: We used qPCR to evaluate the most abundant butyrate-producing species F. prauznitzii, E. rectale and Roseburia spp. and the BCoAT gene, which reflects the butyrogenic capacity of the intestinal microbiota. Fecal samples were collected from healthy kidney donors (n=15), preemptive renal transplant recipients (n=4) and dialysis patients (n=31). Markers of inflammation (CRP and IL-6) and intestinal permeability (D-lactate) were measured in plasma. Results: Patients with ESRD did not have a significantly decreased amount F. prauznitzii, E. rectale and Roseburia spp. or the BCoAT gene. Neither was there a significant correlation with CRP, IL-6 or D-lactate. On the individual level, there were some patients with decreased BCoAT levels and increased levels of CRP, IL-6 and D-lactate. Conclusions: Patients with ESRD do not have a decreased amount of the most abundant butyrate-producing species nor a decreased butyrate-producing capacity.

AB - Background: Chronic kidney disease (CKD) is associated with a decreased intestinal barrier function, causing bacterial translocation over the intestinal wall and triggering a systemic inflammatory response. Butyrate, a short-chain fatty acid produced by certain bacterial strains, is considered instrumental to keep the intestinal barrier intact. There are indications that a decreased amount of these specific bacterial species is part of the cause of the decreased intestinal barrier function in CKD. The aim of this study is (i) to determine if Dutch patients with end-stage renal disease (ESRD) have a decreased amount of butyrateproducing species and butyrate-producing capacity and (ii) whether this correlates with systemic inflammation. Methods: We used qPCR to evaluate the most abundant butyrate-producing species F. prauznitzii, E. rectale and Roseburia spp. and the BCoAT gene, which reflects the butyrogenic capacity of the intestinal microbiota. Fecal samples were collected from healthy kidney donors (n=15), preemptive renal transplant recipients (n=4) and dialysis patients (n=31). Markers of inflammation (CRP and IL-6) and intestinal permeability (D-lactate) were measured in plasma. Results: Patients with ESRD did not have a significantly decreased amount F. prauznitzii, E. rectale and Roseburia spp. or the BCoAT gene. Neither was there a significant correlation with CRP, IL-6 or D-lactate. On the individual level, there were some patients with decreased BCoAT levels and increased levels of CRP, IL-6 and D-lactate. Conclusions: Patients with ESRD do not have a decreased amount of the most abundant butyrate-producing species nor a decreased butyrate-producing capacity.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067629111&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31123416

U2 - 10.2147/IJNRD.S200297

DO - 10.2147/IJNRD.S200297

M3 - Article

VL - 12

SP - 87

EP - 101

JO - International Journal of Nephrology and Renovascular Disease

JF - International Journal of Nephrology and Renovascular Disease

SN - 1178-7058

ER -